Serum β-2 microglobulin predicts mortality in people with diabetes

European Journal of Endocrinology

Volumn 169, Issue 1, 2013, Pages 1-7

  Cheung, Ching Lung ^a   Lam, Karen S L ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AFRICAN AMERICANS; AGED; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MEXICAN AMERICANS; MIDDLE AGED; NUTRITION SURVEYS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; UNITED STATES;

EID: 84879966510     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0003     Document Type: Article

References (24)

1. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS &Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and allcause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology 2004 15 1307-1315. (doi:10.1097/01.ASN.0000123691.46138.E2)
2. de Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, Rifkin DE, Sarnak MJ, Shlipak MG &Siscovick DS. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009 32 1833-1838. (doi:10.2337/dc09-0191)
3. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Diouf M, Choukroun G &Massy ZA. Plasma b-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney International 2012 82 1297-1303. (doi:10.1038/ki.2012.301)
4. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA &Coresh J. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. American Journal of Kidney Diseases 2012 59 653-662. (doi:10.1053/j.ajkd.2011.11.042)
5. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology 2008 3 69-77. (doi:10.2215/CJN.02340607)
6. Shinkai S, Chaves PH, Fujiwara Y, Watanabe S, Shibata H, Yoshida H &Suzuki T. b2-Microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Archives of Internal Medicine 2008 168 200-206. (doi:10.1001/archinternmed.2007. 64)
7. Lonnemann G &Koch KM. b(2)-Microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. Journal of the American Society of Nephrology 2002 13 (Suppl 1) S72-S77.
8. Kong FL, Cheng W, Chen J &Liang Y. D-Ribose glycates b(2)-microglobulin to form aggregates with high cytotoxicity through a ROS-mediated pathway. Chemico-Biological Interactions 2011 194 69-78. (doi:10.1016/j.cbi.2011.08.003)
9. Freeman WM, Bixler GV, Brucklacher RM, Walsh E, Kimball SR, Jefferson LS &Bronson SK. Transcriptomic comparison of the retina in two mouse models of diabetes. Journal of Ocular Biology, Diseases, and Informatics 2009 2 202-213. (doi:10.1007/s12177- 009-9045-3)
10. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD, USA. Department of Health and Human Services, Centers for Disease Control and Prevention (1988-1994), 1996.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009 150 604-612. (doi:10.7326/0003-4819-150-9- 200905050-00006)
12. National Center for Health Statistics. Office of Analysis and Epidemiology, The Third National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File, Mortality follow-up through 2006: Matching Methodology May 2009. Hyattsville, Maryland. (Available at the following address: http:// www.cdc.gov/nchs/data/datalinkage/matching-methodology- nhanes3-final.pdf), 2009.
13. Murray CJ, Dias RH, Kulkarni SC, Lozano R, Stevens GA &Ezzati M. Improving the comparability of diabetes mortality statistics in the U.S. and Mexico. Diabetes Care 2008 31 451-458. (doi:10.2337/dc07-1370)
14. Berhane AM, Weil EJ, Knowler WC, Nelson RG &Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clinical Journal of the American Society of Nephrology 2011 6 2444-2451. (doi:10.2215/ CJN.00580111)
15. Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011 54 32-43. (doi:10.1007/s00125-010- 1854-1)
16. Bruno G, Merletti F, Bargero G, Novelli G, Melis D, Soddu A, Perotto M, Pagano G &Cavallo-Perin P. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 2007 50 941-948. (doi:10.1007/s00125-007-0616-1)
17. Xie J &Yi Q. b2-Microglobulin as a potential initiator of inflammatory responses. Trends in Immunology 2003 24 228-229 (author reply 229-230). (doi:10.1016/S1471- 4906(03)00076-0)
18. Chen NX, O'Neill KD, Niwa T &Moe SM. Signal transduction of b2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. Kidney International 2002 61 414-424. (doi:10.1046/j.1523-1755.2002.00136.x)
19. Nachbaur K, Troppmair J, Bieling P, Kotlan B, Konig P &Huber C. Cytokines in the control of b-2 microglobulin release. I. In vitro studies on various haemopoietic cells. Immunobiology 1988 177 55-65. (doi:10.1016/S0171- 2985(88)80091-3)
20. Fuchs D, Hausen A, Reibnegger G, Werner ER, Felmayer GW &Wachter H. b2-Microglobulin and immune activation. Clinical Chemistry 1989 35 2158-2159.
21. Kim HA, Jeon JY, Yoon JM &Suh CH. b2-Microglobulin can be a disease activity marker in systemic lupus erythematosus. American Journal of the Medical Sciences 2010 339 337-340. (doi:10.1097/ MAJ.0b013e3181d26dfb)
22. Manicourt D, Brauman H &Orloff S. Plasma and urinary levels of b2 microglobulin in rheumatoid arthritis. Annals of the Rheumatic Diseases 1978 37 328-332. (doi:10.1136/ard.37.4.328)
23. Sonikian M, Gogusev J, Zingraff J, Loric S, Quednau B, Bessou G, Siffert W, Drueke TB, Reusch HP &Luft FC. Potential effect of metabolic acidosis on b2-microglobulin generation: in vivo and in vitro studies. Journal of the American Society of Nephrology 1996 7 350-356.
24. Yang J &Yi Q. Killing tumor cells through their surface b(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 2010 116 1638-1645. (doi:10.1002/cncr. 24953)